Objective: Prior studies have found that early HIV protease inhibitors contribute to glucose dysregulation. Few randomized trials have evaluated glucose indices in antiretroviral-naive individuals on newer antiretroviral therapy (ART).
Introduction
Persons living with HIV infection are more likely to develop diabetes mellitus than the general population, likely the consequence of a multitude of factors, including the HIV-1 itself, lipodystrophy, heightened inflammation, an increasing prevalence of obesity, hepatitis C coinfection and racial/ethnic predilection [1] [2] [3] [4] . Some studies have suggested up to a four-fold increase in the relative risk of a diabetes mellitus diagnosis compared with HIV-uninfected controls, even after adjusting for differences in obesity [5, 6] .
The role of individual antiretroviral therapy on the development of diabetes mellitus is often difficult to tease out from other confounding factors, and the impact on glucose varies widely. Some of the nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors are associated with diabetes mellitus as a result of inducing lipodystrophy, mitochondrial toxicity or direct effects on glucose metabolism [1, 3, [7] [8] [9] [10] [11] [12] [13] . The newer protease inhibitors, atazanavir (ATV) and darunavir, appear to have a minimal impact on glucose metabolism in either HIV-infected or HIV-uninfected persons [14] [15] [16] [17] [18] . Similarly, the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) has been associated with only very modest changes in glucose metabolism up to 48 weeks [16, [19] [20] [21] .
We have previously presented data on changes in total body weight, adipose tissue and lean mass after ART initiation in AIDS Clinical Trials Group A5224s, a substudy of A5202, in which HIV-infected treatment-naive participants were randomized in a double-blinded fashion to abacavir/ lamivudine (ABC/3TC) or tenofovir DF/emtricitabine (TDF/FTC) with open-label EFV or atazanavir-ritonavir (ATV/r) [22] [23] [24] [25] [26] . Briefly, randomization to TDF/FTC led to less gain in limb fat, and no significant difference in change in visceral fat at week 96 compared with ABC/3TC [24] . Assignment to ATV/r led to significantly greater increase in total body weight, BMI, limb fat and a trend towards greater increase in visceral fat compared with EFV [24, 27] . Here, we compare the changes in glucose, insulin and the homeostatic model assessment of insulin resistance (HOMA-IR) between the NRTI components and NNRTI/protease inhibitor components. We also explore the association of changes in glucose metabolism with changes in body composition and markers of inflammation.
Materials and methods
A5224s was a substudy of AIDS Clinical Trials Group A5202, in which ART-naive persons aged at least 16 years and with an HIV-1 RNA load more than 1000 copies/ml received blinded TDF/FTC or ABC/3TC, with openlabel EFV or ATV/r at standard doses. The primary analyses of both A5202 and A5224s have been presented previously [22, [24] [25] [26] 28] . Specific A5224s exclusion criteria were uncontrolled thyroid disease or hypogonadism; endocrine diseases, including Cushing's syndrome, diabetes mellitus and the use of growth hormone, anabolic steroids, glucocorticoids or osteoporosis medications (calcium and/or vitamin D were not included).
The duration of the study was 96 weeks after the last A5202 participant enrolled.
Any participant enrolling in A5202 at one of the AIDS Clinical Trials Group sites participating in A5224s and meeting criteria for A5224s was eligible to enroll in the substudy; A5202 randomization was stratified by willingness to enroll into the substudy. Each participant signed a written informed consent before enrollment. The study was approved by the local institutional review board at each site.
On 18 February 2008, after a median follow-up of 97 weeks (range 0-124 weeks; Q1-Q3 58-108 weeks), the Data Safety and Monitoring Board recommended unblinding the NRTI component of the study for participants with screening HIV-1 RNA levels at least 100 000 copies/ml because of excess virological failures associated with ABC/3TC; individuals receiving ABC/3TC were permitted to modify their NRTI regimen [26] .
Clinical assessment and bone density analysis
At baseline, a complete history was obtained and participants underwent a physical examination, including standardized measurement of height and weight. Development of diabetes mellitus while on study was defined as either a clinical diagnosis by a medical provider or a fasting blood sugar at least 126 mg/dl at two separate time points over 1 year. Individuals underwent whole-body dualenergy absorptiometry (DXA) at baseline and at weeks 24, 48 and every 48 weeks until the end of follow-up. Lean body mass was defined as fat-free, bone-free mass as measured by DXA in the anteroposterior view (using Hologic or Lunar scanners). Technicians were instructed to use the same DXA machine on the same participant throughout the study. All DXAs were standardized at the participating sites, and then centrally read (Tufts) by blinded personnel.
Measurement of glucose metabolism and biomarker assays
Fasting samples were obtained after abstaining from food and drink except water for at least 8 h. Glucose values were obtained from a metabolic panel run at the individual sites. Serum and plasma were stored at À808C without prior thawing until analysis. Serum insulin was measured by commercial testing at Quest Diagnostics by radioimmunoassay. Insulin sensitivity by the HOMA-IR was calculated as fasting insulin [mIU/ml] Â fasting glucose [mg/dl]/405, with higher values indicating lower insulin sensitivity [29] . Biomarker assays were analysed as previously described [30] .
Statistical analysis
The current study was a prespecified secondary analysis of A5224s to compare changes from baseline to week 96 in fasting glucose, insulin and HOMA-IR between pooled, randomized NRTI components (ABC/3TC versus TDF/FTC) and NNRTI/protease inhibitor components (ATV/r versus EFV). All analyses were performed using the intent-to-treat principle based on randomized treatment assignment in which all available data were included and modifications to randomized treatment were ignored; no imputations were made for missing values. Supplemental as-treated analyses were performed in which values were censored after a change in the randomized NRTI component (when comparing NRTI components) or NNRTI/protease inhibitor component (when comparing NNRTI/protease inhibitor components).
Because fasting insulin and HOMA-IR were not normally distributed, data were log 10 transformed prior to analysis. The exponential of the estimated mean change in the transformed data was used to obtain the estimated mean fold change; values less than 1 correspond to a decrease from baseline. Differences between assigned study arms for glucose are reported as mean differences and differences for log-transformed data (insulin, HOMA-IR) are reported as the % difference in the mean fold change. The unadjusted effects of the NRTI component and the NNRTI/protease inhibitor component on changes were evaluated separately using twosample t-tests. Linear regression was used to test for prespecified interactions between NRTI and NNRTI/ protease inhibitor components and to evaluate a potential interaction between treatment allocation and screening HIV-1 RNA stratum (<100 000 or !100 000 copies/ml). Additional sensitivity analyses were done for fasting insulin, glucose and HOMA-IR, which excluded results without confirmed fasting status by a food intake case report form or excluded values wherein insulin was more than 50 mIU/ml. Changes from baseline within study arm or regimen component were assessed with one-sample t-tests. Correlations of measures of glucose metabolism with inflammatory markers or measures of body composition were evaluated using Spearman's rank correlation test. In addition, a locally weighted least squares (LOWESS) smooth was overlaid on the scatter plot for visual purposes, using only data points between the 2.5th and 97.5th percentiles for both plotted variables. P values below 0.05 (<0.10 for assessing interactions) were considered statistically significant. Linear regression was used to adjust for baseline and postbaseline factors and explore associations with baseline and postbaseline factors. Univariate associations with a P value less than 0.20 were included in a multivariable model, which utilized backwards selection and only factors with a P value less than 0.05 were retained; NRTI component and NNRTI/protease inhibitor component were retained regardless of P value. Analyses were performed using SAS, version 9.2 (SAS Institute, Cary, North Carolina, USA).
Results

Participant characteristics
A5224s included 271 participants from 37 AIDS Clinical Trials Group sites in the United States and Puerto Rico, randomized to receive ART; two participants were excluded from the analysis for eligibility violations. Sixty-nine participants were randomized to receive EFV as well as TDF/FTC, 70 to EFV as well as ABC/3TC, 65 to ATV/r as well as TDF/FTC, and 65 to ATV/r as well as ABC/3TC. Baseline characteristics are summarized in Table 1 and were balanced across study arms. The median age of the individuals was 38 years, 85% were men and 47% were white, non-Hispanic. The median BMI was 24.9 kg/m 2 , CD4 þ cell count was 233 cells/ml, plasma HIV-1 RNA was 4.6 log 10 copies/ml and 80% had an HIV-1 RNA less than 100 000 copies/ml at study entry. Sixty-six (25%) of A5224s participants prematurely discontinued study follow-up, four (1%) died and 122 (45%) modified the randomized treatment regimen. These details have been previously published [24, 25] . Briefly, 36 participants (13%) had a treatment modification before week 12, 12 (4%) Fig. 1a ). No significant differences in glucose were detected between ABC/3TC and TDF/FTC groups in the as-treated analysis (mean difference ¼ 2.9; 95% CI À0.5 to 6.3;
The mean glucose change in the EFV arm over 96 weeks (4.8; 95% CI 2.6-7.0 mg/dl) was significantly greater than the mean change in the ATV/r arm (0.4; 95% CI À1.8 to 2.6 mg/dl) with a difference of 4.4 (95% CI 1.3-7.5 mg/dl); P ¼ 0.006 (Fig. 1a ). These differences were similar in the as-treated analyses (mean difference ¼ 4.9; 95% CI 1.7-8.0; P ¼ 0.002) and sensitivity analysis excluding persons without confirmed fasting status for glucose measurements (mean difference ¼ 4.7; 95% CI 1.4-8.0; P ¼ 0.005). There was no significant interaction between the NRTI and NNRTI/protease inhibitor components (P ¼ 0.61).
Change in fasting insulin
Overall, the median change in insulin from week 0 to 96 was 0 mIU/ml [interquartile range (IQR) À2 to 4 mIU/ml] and the mean fold change was 1.24 (1.07-1.44) (P ¼ 0.004). The subsequent analyses used log 10 -transformed fasting insulin to account for the skewed distribution of change data. No significant differences in insulin were detected between ABC/3TC and TDF/FTC groups by intent-to-treat (fold change % difference ¼ 3.5; 95% CI À23.0 to 39.1; P ¼ 0.82; Fig. 1b ) or as-treated analyses (fold change % difference ¼ 17.9; 95% CI À14.6 to 62.7; P ¼ 0.31). Similarly, no significant differences in insulin were detected between ATV/r and EFV groups by intent-to-treat (fold change % difference ¼ 5.5; 95% CI À21.5 to 41.9; P ¼ 0.72; Fig. 1b ) or as-treated analysis (fold change % difference ¼ 22.8; 95% CI À10.1 to 67.8;
. Similar results were seen in a sensitivity analysis excluding persons without confirmed fasting state (N ¼ 71) or with insulin values greater than 50 mIU/ml (N ¼ 62), suggestive of nonfasting state at the time of blood sampling. There was no significant interaction between the NRTI and NNRTI/protease inhibitor components (P ¼ 0.65).
Change in insulin sensitivity by HOMA-IR
Overall, the median change in HOMA-IR from week 0 to 96 was 0.09 (IQR À0.28 to 0.81) and the mean fold change was 1.30 (1.11-1.51) (P ¼ 0.001). The subsequent analyses used log 10 -transformed HOMA-IR to account for the skewed distribution of change data. No significant differences in change in insulin sensitivity were detected between ABC/3TC and TDF/FTC groups by intent-to-treat (fold change % difference ¼ 2.5; 95% CI À24.7 to 39.5; P ¼ 0.88; Fig. 1c ) or as-treated analyses (fold change % difference ¼ 20.6; 95% CI À13.6 to 68.3; P ¼ 0.27). Similarly, no significant differences in HOMA-IR were detected between ATV/r and EFV groups by intent-to-treat (fold change % difference ¼ 5.2; 95% CI À30.3 to 29.1; P ¼ 0.73; Fig. 1c ) or as-treated analysis (fold change % difference ¼ 11.2; 95% CI À20.0 to 54.4; P ¼ 0.53). There was no significant interaction between the NRTI and NNRTI/protease inhibitor components (P ¼ 0.97). We did detect a differential treatment effect (interaction) between screening viral load strata and NNRTI/protease inhibitor (P ¼ 0.099) such that persons with persons with a viral load at least 100 000 copies/ml had less increase in HOMA-IR with ATV/r compared with EFV (difference ¼ À31.9; 95% CI À58.1 to 10.7), whereas persons in the viral load less than 100 000 copies/ml strata had greater increase in HOMA-IR with ATV/r than with EFV (difference ¼ 15.2; 95% CI À22.4 to 71.0).
Correlation of change at week 96 in glucose and insulin sensitivity with body composition
Correlation plots were used to investigate the association between week 0-96 changes in glucose metabolism and week 0-96 changes in body composition that occur with ART initiation. Statistically significant weak to moderate positive correlations were detected between the changes in glucose, insulin and HOMA-IR with changes in BMI, LBM, limb fat and trunk fat (Fig. 2) .
Univariate and multivariable linear regression analyses
Baseline variables associated with a change in fasting glucose, insulin and insulin sensitivity are summarized in associated with a greater increase in HOMA-IR (worsened insulin sensitivity), but none of the baseline variables were associated with insulin change (Table 2) . To further explore the significant NNRTI/protease inhibitor treatment effect on change in glucose, in a posthoc analysis, we added postbaseline variables including changes in CD4 þ cell count, and body composition measures and week 96 viral suppression (<50 copies/ml).
In multivariable analyses, assignment to EFV (versus ATV/r), higher baseline HIV-1 RNA and greater change in BMI remained significant independent factors associated with greater increase in glucose (Table 3) .
Correlation with week 96 change in inflammatory markers
Lastly, we investigated the correlation of changes in glucose metabolism after ART initiation with changes in markers of inflammation. Weak but statistically significant negative relationships were detected between the change in glucose and the change in tumour necrosis factor-alpha (TNF-a) (r ¼ À0.21, P ¼ 0.002), soluble vascular adhesion molecule-1 (sVCAM-1) (r ¼ À0.15, P ¼ 0.037), soluble tumour necrosis factor receptor II (sTNF-RII) (r ¼ À0.15, P ¼ 0.033), but not interleukin (IL)-6 (r ¼ 0.03, P ¼ 0.67), high sensitivity C-reactive protein (hs-CRP) (r ¼ 0.02, P ¼ 0.73), soluble intercellular adhesion molecule-1 (sICAM-1) (r ¼ À0.09, P ¼ 0.23) and soluble tumour necrosis factor receptor I (sTNF-RI) (r ¼ À0.12, P ¼ 0.09). Changes in insulin and HOMA-IR were not significantly correlated with markers of inflammation (P > 0.074).
Discussion
Herein, we have demonstrated a significantly larger increase in glucose with assignment to EFV than to ATV/r. Although modest increases in insulin and HOMA-IR were observed across all treatment arms, differences were not significant between arms. Not surprisingly, the increase in glucose, insulin and HOMA-IR correlated with increases in BMI, limb fat and trunk fat. Even after adjusting for changes in body composition in multivariate analyses, the EFV treatment effect on glucose change remained significant. As we have shown previously, persons randomized to EFV had significantly lower gain in BMI than those randomized to ATV/r [31] . The Spearman correlation coefficient of 0.23 between glucose and BMI changes indicated a weak positive relationship, and thus, on the basis of the results of the current analysis and our prior work, the change in BMI only explains a small percentage of the glucose change.
We estimated a mean increase in glucose through week 96 of 4.8 mg/dl in the EFV compared with 0.4 mg/dl in the ATV/r arm, similar changes in magnitude as those
Randomized antiretroviral therapy and glucose metabolism Erlandson et al. 1457 Table 3 . Univariate and multivariable linear regression to assess the association between baseline and postbaseline factors and change in glucose. reported in other studies of shorter duration. Jemsek et al. [16] demonstrated a mean 1 mg/dl difference in the week 48 change in glucose between 100 HIV-infected persons randomized to EFV (increase of 3 mg/dl) compared with 111 randomized to ATV/r (increase of 4 mg/dl) with identical backbone therapy (zidovudine and lamivudine). Nonsignificant decreases in insulin and HOMA-IR were observed in the ATV/r arm and nonsignificant increases were observed in the EFV arm [16] . ACTG Study A5095 randomized participants to triple-NRTI, triple NRTI and EFV, or dual-NRTI and EFV and found significant increases in glucose (mean 6-8 mg/dl) and HOMA-IR across all study arms. Due to virologic inferiority, the initial triple-NRTI group underwent intensification with either EFV or TDF after 24 weeks. A trend towards a significantly greater increase from week 24 in glucose (median 3 mg/dl; P ¼ 0.08) and a significant increase from week 24 in log 10 HOMA-IR (0.13; P ¼ 0.03) was detected in the EFV intensification than in the TDF intensification arm [19] . In STARTMRK, although assignment to EFV was associated with significantly greater 96-week glucose increase (6 mg/dl) than in the raltegravir arm (2 mg/dl; P ¼ 0.025), three (1.1%) individuals in the raltegravir and none of the EFV group developed a fasting glucose more than 250 mg/dl while on study [21] . A cross-sectional, observational study in South Africa found a significantly higher prevalence of diabetes or prediabetes mellitus among persons receiving EFV than those receiving nevirapine (73 versus 27%, P < 0.001), a finding that remained significant in multivariable analysis adjusted for covariates that included body composition, age and CD4 þ count [23] . Interestingly, a small study [32] switching individuals with lipodystrophy from protease inhibitor-based therapy to EFV had a nonsignificant increase in fasting glucose and insulin after 48 weeks on EFV.
Univariate analyses
We had anticipated that inclusion of inflammatory markers would add clinical significance to the changes in glucose, such that increases in markers associated with cardiovascular disease risk (i.e. IL-6, hs-CRP) would be associated with increased glucose, insulin and HOMA-IR. In contrast, we only found significant negative correlations with some inflammatory markers. We hypothesize that our findings reflect that the overall decline in inflammatory markers with ART initiation [30, 33] is greater than changes that might be seen with glucose dysregulation [34] .
We also found an association between higher HIV-1 RNA at treatment initiation and greater glucose increase. Higher HIV-1 RNA (>400 versus <400 copies/ml) has previously been reported as a risk for metabolic syndrome both in observational [35, 36] and treatment initiation studies [37] . The impact of HIV-1 RNA tends to be more apparent through abnormalities in the metabolic syndrome components of blood pressure, triglycerides and high-density lipoprotein (HDL) rather than glucose [35, 38] . Nonetheless, this is yet another factor to support initiation of ART at lower HIV-1 RNA levels.
We acknowledge several limitations of the current study. First, we excluded persons with a diagnosis of diabetes mellitus at baseline; thus, the effect on blood glucose in persons with known diabetes mellitus cannot be evaluated in the context of this study. Our participant population was relatively young, and greater rates of insulin resistance may be observed in older cohorts. Second, we may underestimate the true changes in glucose metabolism through measuring only fasting glucose and insulin. Prior studies have demonstrated that 15% of individuals with normal fasting glucose had evidence of diabetes mellitus or impaired glucose tolerance on a 75 g glucose tolerance test, suggesting that fasting glucose may be relatively insensitive to the diagnosis of diabetes mellitus among HIV-infected persons [39, 40] . Nonetheless, our study measured concomitantly fasting insulin level, and the derived HOMA-IR index has been shown to correlate well with more expensive and cumbersome methods of measuring insulin sensitivity such as hyperinsulinemic-euglycemic clamps [41] . Also, no physical activity data or diary of specific food or drink intake were collected, and these could confound insulin sensitivity. Although sensitivity analyses excluding persons without confirmed fasting state or with insulin levels more than 50 mIU/ml did not show significant differences, we did not confirm fasting state with measurement of C-peptide. Lastly, a large proportion of individuals modified the ART regimens while on study, and week 96 data were not available for all participants: 82% of participants had week 96 fasting glucose available, 78% fasting insulin and 75% HOMA-IR.
The primary strengths of this study lie in the randomized design including four contemporary ART regimens, all with a presumably low risk of metabolic adverse effects. In addition, the inclusion of the two different NRTI backbone arms allowed for analysis of a potential NRTI interaction with protease inhibitor/NNRTI treatment, although this substudy was not specifically powered to detect interactions. The inclusion of body composition data, CD4 þ cell count and HIV-1 RNA allowed for interpretation of changes in glucose metabolism between study arms while considering the effects of individual ART on body composition.
In summary, we detected significantly greater glucose increases among persons treated with EFV than among those treated with ATV/r that persisted in multivariable analyses and was not explained through an increase in BMI. Although the glucose differences that we detected were statistically significant, the clinical significance of an approximately 4 mg/dl difference in glucose between the EFV and ATV/r treatment arms is unclear. However, in the era of HIV as a chronic disease, even modest increases in glucose in the context of concurrent increase in BMI and insulin resistance could have important consequences over decades of treatment. Furthermore, this reinforces the need for healthy lifestyle choices including diet and exercise, as the added impact of EFV may be yet another risk factor for diabetes mellitus in a population of increasing age and obesity [13, 42, 43] . The impact of long-term EFV use on the development of diabetes mellitus should be explored in randomized studies of longer duration.
